Loading organizations...
ABclonal is a life science technology company based in Woburn, Massachusetts, and Wuhan, China, that manufactures biological research reagents, next-generation sequencing kits, and custom monoclonal antibodies. The enterprise operates globally with approximately 520 employees and generates an estimated $28.6 million in annual revenue by supplying a catalog of over 20,000 antibodies and proteins to pharmaceutical companies, academic institutions, and biotechnology firms. The organization has secured $92.9 million in total funding across three rounds, highlighted by a $90 million Series C investment led by Sequoia Capital China and Lynnwood Capital, alongside HighLight Capital. To expand its contract research services and diagnostic market presence, the firm acquired Yurogen Biosystems and its single B-cell recombinant antibody discovery platform in early 2021. The biological reagent manufacturer ABclonal was officially founded in 2011 by chief executive officer Zack Wu.
ABclonal has raised $281.9M across 2 funding rounds.
ABclonal has raised $281.9M in total across 2 funding rounds.
ABclonal has raised $281.9M across 2 funding rounds. Most recently, it raised $190.0M Series D in December 2021.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Dec 1, 2021 | $190M Series D | — | DST Global, Sequoia Capital China | Announced |
| Dec 18, 2020 | $91.9M Series C | Lyfe Capital | — | Announced |
ABclonal Technology is a Massachusetts-based biotechnology company founded in 2011 that develops and manufactures high-quality, cost-effective research reagents and custom services for life science researchers, in vitro diagnostics (IVD), and pharmaceutical companies.[2][3] It offers a broad portfolio including over 10,000 self-manufactured antibodies (notably recombinant rabbit monoclonal antibodies via its proprietary SMab™ Single B cell platform), ELISA kits, proteins, enzymes, molecular biology reagents, NGS library preparation kits, and custom services like antibody development, engineering, and protein expression.[1][2][3] ABclonal serves academic researchers studying areas such as cancer, epigenetics, DNA damage & repair, infectious diseases, and neurodegenerative disorders like Parkinson's, while also supporting industrial R&D with tailored solutions for drug discovery and IVD product development; its growth is evidenced by global R&D centers, ISO9001/ISO13485 certifications, next-day shipping for in-stock items, and rapid portfolio expansion.[1][2][3]
ABclonal Technology was established in 2011 as an innovative biotech firm with a mission to empower biomedical innovation through reliable research tools.[2] Headquartered in Woburn, Massachusetts (500 W Cummings Park, Ste. 6500), it has expanded with R&D centers worldwide and a UK hub in Swansea, reflecting a focus on global technical advancement in protein science and molecular biology.[1][2][3] The company's idea emerged from listening to scientists' needs, translating feedback into products via state-of-the-art platforms like SMab™ for single B cell-based monoclonal antibody discovery, which incubates B cells in vitro for high-affinity recombinant antibodies.[1][2] Early traction came from building a catalog of 10,000+ items and custom services, with pivotal growth in recombinant antibodies and NGS kits, positioning it as a dynamic provider amid rising demand for reproducible reagents.[1][3]
ABclonal rides the wave of advancing biomedical research amid surging demand for precise, reproducible reagents in precision medicine, drug discovery, and diagnostics, fueled by trends like single-cell analysis, epigenetics, and neurodegenerative disease studies (e.g., Parkinson's, muscle development).[1][3][4] Its timing aligns with post-pandemic growth in NGS, IVD raw materials, and custom antibodies, where market forces favor affordable, high-throughput tools over traditional methods—enabling faster innovation for researchers tackling cancer, infectious diseases, and DNA repair.[2][3] By providing scalable platforms like SMab™, ABclonal influences the ecosystem through accelerated publications (e.g., myoblast differentiation, PD research) and support for pharma R&D, democratizing access to advanced antibodies and reducing development timelines.[1][4]
ABclonal is poised for continued expansion by scaling its SMab™ platform and NGS/IVD offerings amid booming biotech R&D investments. Trends like AI-driven antibody design, personalized medicine, and global health challenges (e.g., aging populations driving neurodegeneration research) will shape its trajectory, potentially through more partnerships and portfolio diversification. Its influence may evolve from reagent supplier to key enabler in therapeutic antibody pipelines, solidifying its role as a cost-effective innovator in life sciences.[1][2]
ABclonal has raised $281.9M in total across 2 funding rounds.
ABclonal's investors include DST Global, Sequoia Capital China, LYFE Capital.
